The potentially damaging variants in the LPA, PDIA2, APOBEC1, BRCA2, PCCB, AGPAT2, CREBBP, and MYL5 genes are in each case fairly evenly distributed between the four different dyslipidemia subphenotypes. This evidence concerns the gene MYL5 and metabolic syndrome.